Taiho “Primed And Ready To Go” With Colon Cancer Drug Lonsurf
This article was originally published in The Pink Sheet Daily
Executive Summary
After fast approval of oral chemotherapy combination Lonsurf for late-line colon cancer, U.S. oncology newcomer and Otsuka Holdings subsidiary plans to launch within two weeks at a reasonable price, says CEO Eric Benn.